Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Appili Therapeutics Inc (OP: APLIF ) 0.0213 -0.0003 (-1.39%) Streaming Delayed Price Updated: 2:28 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 630,953 Open 0.0277 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0216 Today's Range 0.0213 - 0.0277 52wk Range 0.0135 - 0.0500 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024 October 03, 2024 Via Investor Brand Network Aditxt Delivers Shareholder Update and 2024 Year-End Plan October 03, 2024 From Aditxt, Inc. Via Business Wire Performance YTD -17.44% -17.44% 1 Month +6.50% +6.50% 3 Month -16.47% -16.47% 6 Month -42.28% -42.28% 1 Year -35.65% -35.65% More News Read More InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval September 24, 2024 Via Investor Brand Network Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 August 29, 2024 From Aditxt, Inc. Via Business Wire TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement August 21, 2024 Via Investor Brand Network Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics August 21, 2024 From Aditxt, Inc. Via Business Wire BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement July 25, 2024 Via Investor Brand Network Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition July 25, 2024 From Aditxt, Inc. Via Business Wire Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) April 02, 2024 From Aditxt, Inc. Via Business Wire Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan December 15, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024 November 13, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy October 25, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update September 27, 2023 From Appili Therapeutics Via Business Wire Appili Therapeutics Presents at the 10th International Tularemia Conference September 27, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension September 25, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024 August 11, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics – Press Release Correction June 23, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results June 23, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole May 24, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference April 18, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer April 03, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023 February 14, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program January 17, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole January 13, 2023 From Appili Therapeutics Inc. Via Business Wire Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy November 14, 2022 From Appili Therapeutics Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.